ACC pipeline
What is next, and who is running it?
The next dated milestone on each program. A hollow marker is a registry primary completion date, not a company readout.
A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.
ClassNone selected
21 of 23 programs on this timeline
202520262027202820292030Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Today
B7-H4-directed ADC 2
EMBLEM-1 first patients dosed, Oct 19, 2026Registry, Feb 2027
Registry, Dec 31, 2029
CXCR1/2 inhibitor 1
SX-682 + DocetaxelPhase 1/2
Registry, Oct 2036
EGFR x MET bispecific antibody 1
AmivantamabPhase 2
No dated milestone in 2025 to 2030
gamma secretase inhibitor 1
No dated milestone in 2025 to 2030
HDAC inhibitor 1
HG146Phase 2
Registry, Dec 31, 2028
MDM2 inhibitor 1
APG-115 (alrizomadlin)Phase 1/2
No dated milestone in 2025 to 2030
multi-kinase TKI 1
Regorafenib (off Label)Phase 2
No dated milestone in 2025 to 2030
multi-kinase TKI with chemotherapy 1
Registry, Jun 2028
MYB mRNA degrader 1
REM-422Phase 1/2
ENA 2026 late-breaking oral 5LBA (updated Phase 1), Nov 19, 2026Initial Phase 2 data (company guidance), H1 2027Registry, Sep 30, 2027
Nectin-4-directed ADC 1
Enfortumab VedotinPhase 2
Registry, Mar 2027
pan-NOTCH transcription inhibitor 1
CB-103Phase 1/2
Registry, Jun 2027
PD-1 x VEGF bispecific 1
IvonescimabPhase 2
Registry, Jul 2027
PSMA radioligand 1
No dated milestone in 2025 to 2030
TrkA inhibitor 1
VMD-928Phase 1/2
Registry, Dec 2027
TROP2-directed ADC 1
Registry, Oct 31, 2028
VEGFR multi-kinase TKI 1
Lenvatinib (off Label)Phase 2
Registry, Dec 2026
VEGFR TKI 1
Axitinib (off Label)Phase 2
No dated milestone in 2025 to 2030
VEGFR/MET/TAM TKI 1
ZanzalintinibPhase 2
Registry, Apr 2029
VEGFR2 TKI 2
RivoceranibTrials stopped
No dated milestone in 2025 to 2030
ApatinibPhase 2
No dated milestone in 2025 to 2030